Page last updated: 2024-12-09

1-hexadecyl-3-methylimidazolium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Hexadecyl-3-methylimidazolium chloride: A powerful tool for research

1-Hexadecyl-3-methylimidazolium chloride, often abbreviated as **[C16mim]Cl**, is an **ionic liquid**.

**What is an ionic liquid?**

Ionic liquids are salts that melt below 100°C, often at room temperature. They are typically composed of an organic cation and an inorganic anion. Unlike traditional solvents, ionic liquids are often non-volatile, non-flammable, and have excellent electrochemical stability.

**Why is [C16mim]Cl important for research?**

[C16mim]Cl is particularly interesting due to its **unique properties** and its potential applications in various fields.

**1. Solvent properties:**

* **High polarity**: This allows [C16mim]Cl to dissolve a wide range of polar and non-polar compounds.
* **Low vapor pressure**: It minimizes evaporation during reactions and experiments, making it suitable for applications where volatile solvents are undesirable.
* **High thermal stability**: It allows for high-temperature reactions without decomposition.
* **Tunable properties**: By altering the cation or anion, researchers can fine-tune the ionic liquid's properties to suit specific applications.

**2. Applications in research:**

* **Catalysis:** [C16mim]Cl can act as a solvent or a catalyst in various reactions, including organic synthesis, enzymatic reactions, and CO2 capture.
* **Electrochemistry:** Its high ionic conductivity and electrochemical stability make it suitable for use in batteries, fuel cells, and electrochemical sensors.
* **Material science:** It can be used in the synthesis of nanoparticles, nanowires, and other advanced materials.
* **Biotechnology:** It can be used for the extraction and purification of biomolecules, like proteins and enzymes.

**3. Environmental benefits:**

* **Sustainable alternative**: It can replace volatile organic solvents, reducing the environmental impact of chemical processes.
* **Biodegradable**: Some ionic liquids, including [C16mim]Cl, have shown potential for biodegradability, making them more environmentally friendly.

**Overall, 1-hexadecyl-3-methylimidazolium chloride is a versatile and powerful tool for research, offering numerous potential applications in various fields.** Its unique properties, combined with its environmental benefits, make it an attractive alternative to traditional solvents.

**Note:** While [C16mim]Cl has great potential, it's crucial to understand its potential toxicity and environmental impact before utilizing it in research. Further investigation and optimization are necessary for safer and more sustainable applications.

1-hexadecyl-3-methylimidazolium chloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734231
CHEMBL ID595912
SCHEMBL ID295427
MeSH IDM0534923

Synonyms (25)

Synonym
nsc-747260
CHEMBL595912
61546-01-8
1-hexadecyl-3-methylimidazolium chloride
nsc747260
dtxcid1027899
cas-61546-01-8
dtxsid8047923 ,
NCGC00258154-01
tox21_200600
1-methyl-3-hexadecyl imidazolium chloride
ZCPPLZJPPBIWRU-UHFFFAOYSA-M
SCHEMBL295427
H1632
mfcd03427608
1-methyl-3-hexadecylimidazolium chloride
1-hexadecyl-3-methylimidazol-3-ium;chloride
3-hexadecyl-1-methyl-1h-imidazol-3-ium chloride
BS-52179
eq4uws7wun ,
1-cetyl-3-methylimidazolium chloride
1h-imidazolium, 3-hexadecyl-1-methyl-, chloride (1:1)
3-hexadecyl-1-methylimidazolium chloride
CS-0378407
F71870
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency81.39810.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency65.08570.002541.796015,848.9004AID1347397; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency57.99453.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency16.03160.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency41.45440.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency41.45440.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency10.56060.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.90740.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency78.60530.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency46.50040.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.14690.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency70.05700.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency32.46300.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.15370.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.24460.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency18.03440.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency58.42300.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency7.86050.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.71580.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency59.56470.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency51.36680.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency36.94630.023723.228263.5986AID743222; AID743223
caspase-3Homo sapiens (human)Potency78.60530.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.42030.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency70.05700.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency56.13970.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency34.99500.154917.870243.6557AID1346877; AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency40.608219.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency19.91910.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.64130.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency56.13970.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency19.24530.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency24.85720.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency35.87530.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency24.85720.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency6.42230.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency5.56480.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID455378Anticancer activity against human MDA-MB-468 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455637Anticancer activity against human U251 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455349Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455345Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455328Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455356Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455621Anticancer activity against human NCI-H23 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455622Anticancer activity against human NCI-H322M cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455363Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455651Anticancer activity against human SKOV3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455375Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455666Anticancer activity against human MDA-MB-435 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455661Anticancer activity against human DU145 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455626Anticancer activity against human HCC2998 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455663Anticancer activity against human NCI/ADR-RES cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455364Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455657Anticancer activity against human SN12C cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455618Anticancer activity against human HOP62 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455331Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455330Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455335Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455377Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455361Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455324Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455620Anticancer activity against human NCI-H226 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455351Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455656Anticancer activity against human RXF393 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455659Anticancer activity against human UO31 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455343Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455368Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455646Anticancer activity against human IGROV1 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455332Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455645Anticancer activity against human UACC62 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455369Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455326Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455366Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455340Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455358Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455334Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455353Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455654Anticancer activity against human ACHN cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455650Anticancer activity against human OVCAR8 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455341Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455338Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455357Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455616Anticancer activity against human A549 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455629Anticancer activity against human HT-29 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455322Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455374Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455371Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455339Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455359Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455625Anticancer activity against human COLO205 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455320Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455346Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455635Anticancer activity against human SNB19 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455630Anticancer activity against human KM12 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455319Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455365Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455372Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455642Anticancer activity against human SK-MEL-28 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455354Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455633Anticancer activity against human SF295 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455373Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455348Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455327Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455370Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455337Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455649Anticancer activity against human OVCAR5 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455342Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455612Anticancer activity against human K562 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455628Anticancer activity against human HCT15 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455631Anticancer activity against human SW620 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455660Anticancer activity against human PC3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455362Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455640Anticancer activity against human M14 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455639Anticancer activity against human MALME-3M cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455668Anticancer activity against human T47D cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455336Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455347Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455634Anticancer activity against human SF539 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455647Anticancer activity against human OVCAR-3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455665Anticancer activity against human Hs 578T cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455355Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455667Anticancer activity against human BT549 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455325Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455652Anticancer activity against human 786-0 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455615Anticancer activity against human SR cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455627Anticancer activity against human HCT116 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455350Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455333Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455655Anticancer activity against human Caki1 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455619Anticancer activity against human HOP92 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455658Anticancer activity against human TK10 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455613Anticancer activity against human MOLT4 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455624Anticancer activity against human NCI-H522 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455352Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455376Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455662Anticancer activity against human MCF7 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455623Anticancer activity against human NCI-H460 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455329Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455321Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455360Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455323Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455611Anticancer activity against human HL-60(TB) cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455367Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455664Anticancer activity against human MDA-MB-231 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455653Anticancer activity against human A498 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455614Anticancer activity against human RPMI8266 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455643Anticancer activity against human SK-MEL-5 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455648Anticancer activity against human OVCAR4 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455379Anticancer activity against human CCRF-CEM cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455644Anticancer activity against human UACC257 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455344Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455638Anticancer activity against human LOXIMVI cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455641Anticancer activity against human SK-MEL-2 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455632Anticancer activity against human SF268 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455636Anticancer activity against human SNB75 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455669Anticancer activity against human MDA-MB-468 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's9 (90.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.31 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]